Decmber 17, 2021

Name of listed company: Chugai Pharmaceutical Co., Ltd.

Code number:

4519 (1st Section of Tokyo Stock Exchange)

Head office:

1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo

President & CEO:

Osamu Okuda

Inquiries to:

Toshiya Sasai, Head of Corporate Communications Dept.

Tel:+81-(0)3-3273-0554

Notice of Board of Director's Resolution on Application for New

Market Segment "Prime Market"

Chugai Pharmaceutical Co., Ltd. (hereafter the "Company") announces that the Company resolved at the meeting of its Board of Directors held today, to apply for listing on the "Prime Market," one of the new market segments of the Tokyo Stock Exchange (TSE).

On July 9, 2021, the Company received the notice of initial assessment by the TSE, confirming that it is in compliance with the continued listing criteria for the Prime Market in the new market segments.

The Company will follow the prescribed procedures related to the application for the selection of the new market segments in accordance with the schedule set by the TSE.

###

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 17 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2021 08:08:05 UTC.